3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
3
Lymphoid
3
CNS
3
Sarcoma
2
Plasma cell
2
Myeloid
2
Dermatologic
2
Classical hematology
2
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Wilms Tumor
1
Sarcoma, Ewing
1
Rhabdomyosarcoma
1
Neuroblastoma
1
Neoplasms, Germ Cell and Embryonal
1
Hepatoblastoma
1
Interventions
Magnetic Resonance Spectroscopy
98
Specimen Handling
79
pembrolizumab
75
enzalutamide
63
Nivolumab
59
Gemcitabine
54
Docetaxel
50
apalutamide
42
Radiosurgery
41
Abiraterone Acetate
40
Androgen Antagonists
39
Prednisone
38
Biopsy
37
darolutamide
35
Cisplatin
35
cabozantinib
31
Radiotherapy
31
Carboplatin
28
Pluvicto
27
abiraterone
26
enfortumab vedotin
24
Ipilimumab
24
Radiation
23
durvalumab
22
atezolizumab
22
Leuprolide
20
olaparib
18
X-Rays
18
Standard of Care
18
avelumab
17
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Vorinostat
×
Genitourinary
×
90 days
×
Clear all
NCT04308330
2026-04-15
NYMC195
New York Medical College
Phase 1
Recruiting
30 enrolled